目的：探讨微小RNA-145（miR-145）、结缔组织生长因子（CTGF）在肺腺癌中的表达关系及其临床意义。方法：收集2012年6月至2014年3月于我院诊治并经病理证实的肺腺癌组织标本95例，同时取癌旁正常肺组织为正常组（95例）。实时定量聚合酶链反应（qRT-PCR）法检测肺腺组织中miR-145与CTGF表达量，免疫组化法检测肺腺组织中CTGF蛋白表达，根据检测结果将miR-145分为高表达组与低表达组，CTGF分为阳性表达组与阴性表达组，分析miR-145、CTGF表达与肺腺癌临床病理参数的关系，Pearson法对miR-145与CTGF进行相关性分析，Kaplan-Meier法对肺腺癌患者的生存情况进行分析。结果：肺腺癌组织中miR-145表达量显著低于正常组（P<0.05），而CTGF表达量显著高于正常组（P<0.05），且肺腺癌组织中CTGF蛋白阳性率显著高于正常组（P<0.05）；miR-145、CTGF表达均与临床分期、淋巴结转移、TNM分期、病理分级、胸膜浸润显著相关（P<0.05）；Pearson相关性分析结果显示miR-145与CTGF呈显著负相关（r=-0.512，P<0.05）；Kaplan-Meier曲线显示肺腺组织中miR-145高表达组无病生存期（DFS）、总生存期（OS）显著高于低表达组，CTGF阴性表达组DFS、OS均显著高于阳性表达组，差异均具有统计学意义（P<0.05）。结论：与正常组相比，肺腺癌中miR-145下调表达而CTGF上调表达，两者呈负相关且与预后有关，可作为早期诊断肺腺癌以及评定患者预后的指标。

[1] 徐艳,沈小星,刘标,等.肺腺癌中PLK1的异常表达及其临床病理意义[J].东南大学学报(医学版),2017,36(5):804-810.
[2] YIN Q W,SUN X F,YANG G T,et al.Increased expression of microRNA-150 is associated with poor prognosis in non-small cell lung cancer[J].International Journal of Clinical and Experimental Pathology,2015,8(1):842-846.
[3] 付强,成静,张金岱,等.MiR-145调节蛋白偶联受体98抑制结直肠癌细胞的奥沙利铂耐药性[J].中华胃肠外科杂志,2017,20(5):566-573.
[4] ALAM K J,MO J S,HAN S H,et al.MicroRNA 375 regulates proliferation and migration of colon cancer cells by suppressing the CTGF-EGFR signaling pathway[J].International Journal of Cancer,2017,141(8):1614-1629.
[5] HEHR T.Role of primary radiotherapy plus deep regional hyperthermia in advanced stage FIGO Ⅱb-Ⅳ cervical carcinoma[J].Strahlenther Onkol,2000,176(10):485-486.
[6] 叶波,赵珩.第八版国际肺癌TNM分期修订稿解读[J].中国肺癌杂志,2016,19(6):337-342.
[7] 李琦,罗天友,黄兴涛,等.能谱CT定量参数评估非小细胞肺癌病理分化程度[J].中国医学摄影技术,2016,32(11):1678-1682.
[8] ZHU Y C,LIAO X H,WANG W X,et al.Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma[J].Thoracic Cancer,2018,9(2):324-327.
[9] 肖旻,徐秋贞.磨玻璃结节肺腺癌CT征象与病理分类及EGFR、ALK基因突变相关性的研究进展[J].东南大学学报(医学版),2017,36(3):500-503.
[10] LIN Z,ZHOU Z,GUO H,et al.Long noncoding RNA gastric cancer-related lncRNA1 mediates gastric malignancy through miRNA-885-3p and cyclin-dependent kinase 4[J].Cell Death & Disease,2018,9(6):607.
[11] CRISTOBAL I,SANZ-ALVAREZ M,TORREJON B,et al.Potential therapeutic impact of miR-145 deregulation in colorectal cancer[J].Molecular Therapy,2018,16(18):30211-30219.
[12] TAKAI T,YOSHIKAWA Y,INAMOTO T,et al.A novel combination RNAi toward warburg effect by replacement with miR-145 and silencing of PTBP1 induces apoptotic cell death in bladder cancer cells[J].International Journal of Molecular Sciences,2017,18(1):179-187.
[13] MO D,YANG D,XIAO X,et al.MiRNA-145 suppresses lung adenocarcinoma cell invasion and migration by targeting N-cadherin[J].Biotechnology Letters,2017,39(5):701-710.
[14] 夏凡,王仪民,王辉.P53通过促进miR-145的表达抑制肺腺癌A549细胞的干细胞特性[J].中国肿瘤生物治疗杂志,2017,24(1):58-63.
[15] LI J,GAO X,JI K,et al.Differential expression of CCN family members CYR611,CTGF and NOV in gastric cancer and their association with disease progression[J].Oncology Reports,2016,36(5):2517-2525.
[16] CAI Y,HUANG G,MA L,et al.Smurf2,an E3 ubiquitin ligase,interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition[J].Biochimica et Biophysica Acta,2018,1865(2):297-308.
[17] 彭浩,宋立伟,周正,等.乳腺癌患者血清CTGF、Six1水平观察[J].山东医药,2016,56(23):27-30.
[18] HAN Q,ZHANG H Y,ZHONG B L,et al.MicroRNA-145 inhibits cell migration and invasion and regulates epithelial-mesenchymal transition (EMT) by targeting connective tissue growth factor (CTGF) in esophageal squamous cell carcinoma[J].Medical Science Monitor,2016,22:3925-3934.